Oxygenta Pharmaceutical Limited (Scrip: 524636) has received approval from the BSE Limited (BSE) for the reclassification of four individuals from the "Promoter/Promoter Group" category to the "Public" category. This development marks a significant change in the company's shareholding structure.

Key Details of the Reclassification

The BSE granted its no-objection through a letter dated October 16, 2025, in response to the company's application submitted on August 29, 2025. The individuals to be reclassified are:

Next Steps for Oxygenta Pharmaceutical

Following this approval, Oxygenta Pharmaceutical Limited is required to take several important steps:

1. Call a shareholders' meeting to seek approval for the reclassification.
2. Ensure compliance with the requirements of Regulation 31A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
3. Make subsequent relevant disclosures of material events related to this reclassification.

The company's Company Secretary & Compliance Officer, Kumkum Bajaj, confirmed that Oxygenta Pharmaceutical will proceed with all necessary steps in accordance with regulatory requirements.

This reclassification may impact the company's shareholding structure and could be of interest to investors and market analysts tracking Oxygenta Pharmaceutical Limited's stock.

Oxygenta Pharmaceutical has announced significant changes in its leadership structure and promoter classification, signaling a shift in the company's ownership and management.

Key Leadership Changes

The pharmaceutical company reported the resignation of Mr. Vankineni Sai Sudhakar from his positions as Managing Director and Chief Financial Officer, effective August 18, 2025. In his resignation letter, Mr. Sudhakar cited the change in ownership and management of the company as the reason for his departure.

Additionally, Mr. Sanagari Kondal Reddy stepped down from his role as Independent Director on the same date, also attributing his resignation to the change in the company's management following a takeover.

Promoter Reclassification

In a significant move, Oxygenta Pharmaceutical's board approved the reclassification of four promoter group shareholders to public shareholders. This decision, subject to necessary approvals from stock exchanges and shareholders, affects the following individuals:

The reclassification request, dated August 19, 2025, is in accordance with Regulation 31A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Board Committee Restructuring

Following these changes, Oxygenta Pharmaceutical has reconstituted its board committees. The new structure of key committees is as follows:

Audit Committee

• Chairman: Sidda Reddy Kanuparthi (Additional Director - Independent)
• Members: Sharvari Swapnil Shinde, Veera Reddy Arava (both Additional Directors - Independent), and Chandra Mouliswar Reddy (Additional Director - Executive)

Nomination and Remuneration Committee

• Chairman: Veera Reddy Arava (Additional Director - Independent)
• Members: Sidda Reddy Kanuparthi and Sharvari Swapnil Shinde (both Additional Directors - Independent)

Annual General Meeting

The company has scheduled its Annual General Meeting for the financial year 2024-25 on September 19, 2025, to be held via video conferencing. M/s. Aakanksha Dubey & Co., Practicing Company Secretary, has been appointed as the scrutinizer for e-voting at the AGM.

These developments mark a significant transition period for Oxygenta Pharmaceutical, potentially indicating a new direction for the company under its changing ownership structure.